Allergan Says Deserted Drug Rule Weakens $680M Fraud Suit
By Alyssa Aquino · May 17, 2024, 9:24 PM EDT
Allergan drew a Maryland federal court's attention to the Centers for Medicare & Medicaid Services' abandonment of a regulation clarifying drug pricing, arguing the move undermined a whistleblower's claims that it...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login